protein

LILRB2/CD85d/ILT-4 Protein, Cynomolgus (HEK293, Fc)

HY-P77739

20 μg;50 μg;100 μg

170;320;510 USD

LILRB2/CD85d/ILT-4 Protein, Cynomolgus (HEK293, Fc)

proteins

HEK293

20 μg;50 μg;100 μg

170;320;510 USD

The LILRB2/CD85d/ILT-4 protein is a receptor for class I MHC antigens and can recognize multiple HLA alleles. It crucially downregulates the immune response and builds tolerance. LILRB2/CD85d/ILT-4 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived LILRB2/CD85d/ILT-4 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of LILRB2/CD85d/ILT-4 Protein, Cynomolgus (HEK293, Fc) is 434 a.a., with molecular weight of 80-90 kDa.

Cynomolgus

The LILRB2/CD85d/ILT-4 Protein serves as a receptor for class I MHC antigens, demonstrating recognition across a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G, and HLA-F alleles. It plays a crucial role in immune response down-regulation and the establishment of tolerance. Specifically, it recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide, leading to the differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, crucial for maintaining maternal-fetal tolerance. LILRB2 competes with CD8A for binding to class I MHC antigens and inhibits FCGR1A-mediated cellular responses, including phosphorylation of proteins and mobilization of intracellular calcium ions. Moreover, it interacts with PTPN6 when phosphorylated and binds to FCGR1A. The direct interactions with peptide-bound HLA-G-B2M and HLA-F-B2M further highlight its involvement in immune modulation.

CD85d; ILT4; ILT-4; ILT4CD85d; LILRB2; LIR2; MIR10

Greater than 95% as determined by Tris-Bis PAGE.

Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

Room temperature in continental US; may vary elsewhere.